Gastric Cancer

Introduction

Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease. The recent approval of Herceptin (trastuzumab; Roche/Chugai) may pave the way for the introduction of more novel drugs

Scope

- Analysis of the gastric cancer market based on a survey of 180 oncologists and GI specialists, supported by interviews with key opinion leaders.
- Epidemiologic forecasts of the gastric cancer patient populations in the seven major pharmaceutical markets.
- In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for gastric cancer patients.
- Discussion of unmet needs and overview of late-stage pipeline drugs.

Research and analysis highlights

Despite a declining trend in incidence rates, the total incidence of gastric cancer in the seven major pharmaceutical markets is forecast to increase over the next decade, driven by the aging populations in these countries. The number of incident cases is forecast to reach over 250,000 cases by the end of 2020.

Because most patients with localized gastric cancer suffer a recurrence, survival is modest for patients with resectable disease. The best outcomes are seen in Japan, where relapse rates are lower compared with the West. In unresectable gastric cancer, survival is very poor and metastatic patients rarely live for more than 11.5 years.

There are currently five drugs in company-sponsored Phase III development for advanced gastric cancer, all of which are molecular targeted therapies. While the extent to which these agents will improve patient outcomes remains to be seen, physicians are generally optimistic about the incorporation of these drugs into treatment.

Key reasons to purchase this research

- Understand prescribing trends in the gastric cancer market
- Examine unmet need within the gastric cancer market and identify opportunities for new product development
- Enhance commercial positioning by increasing understanding of current dynamics within the gastric cancer market

Table of Contents

- Italy
- Spain
- UK

3. EPIDEMIOLOGY

- Introduction and background
- Key points
- Disease definition and diagnosis criteria
- Global variation and historical trends
    - Contemporary trends
- Risk factors
    - Dietary
    - Helicobacter pylori infection
    - Tobacco smoking
    - Family history
- Epidemiologic forecasting of gastric cancer
    - Sources of epidemiologic data
- Description of methods
    - Statistical analysis
- Results
    - Current incident cases and future trends of gastric cancer
    - Segmentation of incident cases
- Discussion
    - US
    - Japan
    - Europe
    - Strengths of Datamonitor's epidemiologic projections
- Conclusions

4. PATIENT SEGMENTATION

FIGURES